- Conditions
- Breast Cancer
- Interventions
- carboplatin, paclitaxel
- Drug
- Lead sponsor
- Theradex
- Industry
- Eligibility
- 18 Years and older · Female only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2001
- U.S. locations
- 25
- States / cities
- Springdale, Arkansas • Monterey, California • Pomona, California + 22 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 961–984
of 1,429
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- pembrolizumab/vibostolimab, durvalumab, cisplatin, pemetrexed, etoposide, carboplatin, paclitaxel, thoracic radiotherapy
- Biological · Drug · Radiation
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 610 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 21
- States / cities
- Long Beach, California • Los Angeles, California • Hollywood, Florida + 18 more
- Conditions
- Metastatic Non-small Cell Lung Cancer
- Interventions
- Pembrolizumab Formulated with Berahyaluronidase Alfa, Pemetrexed, Cisplatin, Carboplatin, Paclitaxel, Nab-paclitaxel, Pembrolizumab, Filgrastim, Pegylated filgrastim
- Biological · Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 377 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 9
- States / cities
- Phoenix, Arizona • Clermont, Florida • Orange City, Florida + 6 more
- Conditions
- Fallopian Tube Carcinoma, Recurrent Ovarian Cancer, Primary Peritoneal Carcinoma, Recurrent Endometrial Cancer
- Interventions
- Lenvatinib Mesylate, Paclitaxel, Pharmacological Study
- Drug · Other
- Lead sponsor
- Floor Backes
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2022
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Invasive Breast Cancer
- Interventions
- Doxil, Paclitaxel, Cyclophosphamide, Avastin
- Drug
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 19 Years and older · Female only
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2015
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
- Conditions
- Extragonadal Germ Cell Tumor, Testicular Germ Cell Tumor
- Interventions
- cisplatin, ifosfamide, paclitaxel, vinblastine
- Drug
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 18 Years to 120 Years · Male only
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2005
- U.S. locations
- 78
- States / cities
- Anniston, Alabama • La Jolla, California • Los Angeles, California + 57 more
- Conditions
- Pancreatic Adenocarcinoma, Resectable Pancreatic Cancer
- Interventions
- Nab paclitaxel, Gemcitabine, NovoTTF-200T(P)
- Drug · Device
- Lead sponsor
- Ashish Manne
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 38 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Melanoma
- Interventions
- Sorafenib (Nexavar, BAY43-9006), Carboplatin/Paclitaxel, Placebo
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 270 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2009
- U.S. locations
- 19
- States / cities
- Birmingham, Alabama • Tucson, Arizona • Los Angeles, California + 16 more
- Conditions
- Advanced Solid Tumors
- Interventions
- TAS-119, Paclitaxel
- Drug
- Lead sponsor
- Taiho Oncology, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 4
- States / cities
- Aurora, Colorado • St Louis, Missouri • New York, New York + 1 more
- Conditions
- Esophageal Cancer, Gastric Cancer
- Interventions
- cisplatin, irinotecan hydrochloride, paclitaxel, conventional surgery, radiation therapy
- Drug · Procedure · Radiation
- Lead sponsor
- Eastern Cooperative Oncology Group
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 97 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2009
- U.S. locations
- 23
- States / cities
- Denver, Colorado • Newark, Delaware • Gainesville, Florida + 17 more
- Conditions
- Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer
- Interventions
- Paclitaxel, Carboplatin, Avastin
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 46 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2021
- U.S. locations
- 5
- States / cities
- Baltimore, Maryland • Boston, Massachusetts • Philadelphia, Pennsylvania + 2 more
- Conditions
- Neoplasms
- Interventions
- RG1507, RO1507, bevacizumab [Avastin], capecitabine [Xeloda], carboplatin, cetuximab, docetaxel, erlotinib [Tarceva], etoposide, gemcitabine, irinotecan, mFOLFOX6, paclitaxel, pemetrexel, sorafenib, temozolomide, trastuzumab [Herceptin]
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 104 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2012
- U.S. locations
- 8
- States / cities
- Tucson, Arizona • San Francisco, California • Santa Monica, California + 5 more
- Conditions
- Male Breast Carcinoma, Stage IIA Breast Cancer AJCC v6 and v7, Stage IIB Breast Cancer AJCC v6 and v7, Stage IIIA Breast Cancer AJCC v7, Stage IIIB Breast Cancer AJCC v7, Stage IIIC Breast Cancer AJCC v7
- Interventions
- Laboratory Biomarker Analysis, Lapatinib Ditosylate, Paclitaxel, Trastuzumab
- Other · Drug · Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 305 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2024
- U.S. locations
- 317
- States / cities
- Tucson, Arizona • Fort Smith, Arkansas • Burbank, California + 222 more
- Conditions
- Resectable Cholangiocarcinoma, Stage IB Intrahepatic Cholangiocarcinoma AJCC v8, Stage II Intrahepatic Cholangiocarcinoma AJCC v8, Stage III Intrahepatic Cholangiocarcinoma AJCC v8, Stage IIIA Intrahepatic Cholangiocarcinoma AJCC v8, Stage IIIB Intrahepatic Cholangiocarcinoma AJCC v8
- Interventions
- Cisplatin, Gemcitabine, Nab-paclitaxel
- Drug
- Lead sponsor
- Emory University
- Other
- Eligibility
- 19 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2023
- U.S. locations
- 7
- States / cities
- Atlanta, Georgia • Rochester, Minnesota • Portland, Oregon + 2 more
- Conditions
- Pancreatic Cancer
- Interventions
- LY2090314, FOLFOX, Gemcitabine, Nab-paclitaxel
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 2
- States / cities
- Jacksonville, Florida • Rochester, Minnesota
- Conditions
- Solid Tumor, Colorectal Cancer, Cholangiocarcinoma, Bladder Cancer, Ovarian Cancer, Gastric Cancer, Palpable Subcutaneous Malignant Lesions, Renal Cell Carcinoma, Melanoma, Epithelial Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer
- Interventions
- TRK-950, Irinotecan, Leucovorin, 5-FU, Gemcitabine, Cisplatin, Carboplatin, Ramucirumab, Paclitaxel, Nivolumab, Pembrolizumab, Imiquimod Cream, Bevacizumab, PLD
- Biological · Drug
- Lead sponsor
- Toray Industries, Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 138 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2026
- U.S. locations
- 13
- States / cities
- Scottsdale, Arizona • Tucson, Arizona • Los Angeles, California + 10 more
- Conditions
- Breast Cancer
- Interventions
- TAC chemotherapy, TC chemotherapy, Dose Dense AC or FEC100 followed by paclitaxel or docetaxel chemotherapy, TCH chemotherapy, T + trastuzumab followed by CEF + trastuzumab, Dose dense AC followed by T + trastuzumab, Dose dense AC followed by T + trastuzumab + pertuzumab, PTH followed by dose dense AC of FEC
- Drug
- Lead sponsor
- Agendia
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 226 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2017
- U.S. locations
- 9
- States / cities
- Mobile, Alabama • Clearwater, Florida • Miami, Florida + 6 more
- Conditions
- Brenner Tumor, Fallopian Tube Cancer, Ovarian Clear Cell Cystadenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian Mucinous Cystadenocarcinoma, Ovarian Serous Cystadenocarcinoma, Ovarian Undifferentiated Adenocarcinoma, Stage III Ovarian Epithelial Cancer, Stage IV Ovarian Epithelial Cancer
- Interventions
- paclitaxel, carboplatin, erlotinib
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 56 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2010
- U.S. locations
- 1
- States / cities
- The Bronx, New York
- Conditions
- Endometrial Adenosquamous Carcinoma, Endometrial Clear Cell Adenocarcinoma, Endometrial Mixed Adenocarcinoma, Endometrial Serous Adenocarcinoma, Endometrial Squamous Cell Carcinoma, Endometrial Undifferentiated Carcinoma, Recurrent Uterine Corpus Carcinoma, Stage IIIA Uterine Corpus Cancer, Stage IIIC Uterine Corpus Cancer, Stage IVA Uterine Corpus Cancer, Stage IVB Uterine Corpus Cancer
- Interventions
- Cisplatin, Doxorubicin Hydrochloride, Filgrastim, Paclitaxel, Pegfilgrastim
- Drug · Biological
- Lead sponsor
- Gynecologic Oncology Group
- Network
- Eligibility
- Female only
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2016
- U.S. locations
- 9
- States / cities
- Hartford, Connecticut • New Britain, Connecticut • Chicago, Illinois + 6 more
- Conditions
- Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma, Cervical Squamous Cell Carcinoma, Not Otherwise Specified, Recurrent Cervical Carcinoma, Stage IVB Cervical Cancer AJCC v6 and v7
- Interventions
- Cisplatin, Laboratory Biomarker Analysis, Paclitaxel, Veliparib
- Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 37 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2017
- U.S. locations
- 25
- States / cities
- Los Angeles, California • Augusta, Georgia • Chicago, Illinois + 18 more
- Conditions
- Breast Cancer, Lung Cancer, Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- Abraxane, Alimta
- Drug
- Lead sponsor
- University of California, Davis
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 49 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2014
- U.S. locations
- 1
- States / cities
- Sacramento, California
- Conditions
- Vascular Disease, Peripheral
- Interventions
- Nanoparticle Paclitaxel
- Drug
- Lead sponsor
- Celgene Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 7
- States / cities
- Sacramento, California • Gainsville, Florida • Davenport, Iowa + 4 more
- Conditions
- Lung Cancer
- Interventions
- bryostatin 1, paclitaxel
- Drug
- Lead sponsor
- University of Chicago
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2003
- U.S. locations
- 10
- States / cities
- Chicago, Illinois • Decatur, Illinois • Evanston, Illinois + 5 more
- Conditions
- Clinical Stage II Esophageal Adenocarcinoma AJCC v8, Clinical Stage III Esophageal Adenocarcinoma AJCC v8, Clinical Stage III Gastric Cancer AJCC v8, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IV Esophageal Adenocarcinoma AJCC v8, Clinical Stage IV Gastric Cancer AJCC v8, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Locally Advanced Esophageal Adenocarcinoma, Locally Advanced Gastric Adenocarcinoma, Locally Advanced Gastroesophageal Junction Adenocarcinoma, Metastatic Esophageal Adenocarcinoma, Metastatic Gastric Adenocarcinoma, Metastatic Gastroesophageal Junction Adenocarcinoma, Unresectable Esophageal Adenocarcinoma, Unresectable Gastric Adenocarcinoma, Unresectable Gastroesophageal Junction Carcinoma
- Interventions
- Biospecimen Collection, Computed Tomography, Futibatinib, Magnetic Resonance Imaging, Paclitaxel, Ramucirumab
- Procedure · Drug · Biological
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2027 – 2031
- U.S. locations
- 2
- States / cities
- Chicago, Illinois • Columbus, Ohio